How to develop a successful cancer drug - Molecules to medicines or targets to treatments?

European Journal of Cancer

Volumn 41, Issue 5, 2005, Pages 676-682

  Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer drug; Lung; Targets; Treatment; Trials

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AMINOPTERIN; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXORUBICIN; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IMATINIB; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVELBINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; RALTITREXED; SORAFENIB; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TOBACCO SMOKE; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG COST; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 14844328698     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.024     Document Type: Article

References (27)

1. Available from: http://www.who.int/cancer/en/
2. R. Peto, and A.D. Lopez Future worldwide health effects of current smoking patterns C.E. Koop C.E. Pearson M.R. Schwarz Critical issues in global health 2001 Jossey-Bass San Francisco (CA)
3. R. Peto, S. Darby, and H. Deo Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies Br Med J 321 2000 323 329
4. Available from: http://www.cancerresearchuk.org/
5. C. Delbaldo, S. Michiels, and N. Syz Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 2004 470 484
6. B.A. Chabner, C.J. Allegra, and G.A. Curt Polyglutamation of methotrexate. Is methotrexate a prodrug J Clin Invest 76 1985 907 912
7. G.J. Peters, and G. Jansen Antimetabolites R.L. Souhami I. Tannock P. Hohenberger J.-C. Horiot Oxford textbook of oncology 2nd ed. 2002 Oxford Press Oxford (UK) 663 713
8. C. Niyikiza, S.D. Baker, and D.E. Seitz Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy Mol Cancer Ther 1 2002 545 552
9. L. Mendelsohn, C. Shih, and V.J. Chen Enzyme inhibition, polyglutamation, and effect of LY231514 (MTA) on purine biosynthesis Semin Oncol 26 Suppl. 6 1999 42 47
10. V.J. Chen, J.R. Bewley, and S.L. Andis Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells Semin. Oncol. 26 Suppl. 6 1999 48 54
11. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
12. N. Dyson The regulation of E2F by pRb-family proteins Gene Dev 12 1998 2245 2262
13. C.J. Sherr, and R.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Gene Dev 13 1999 1501 1512
14. Y. Sekido, K.M. Fong, and J.D. Minna Molecular genetics of lung cancer Annu Rev Med 54 2003 73 87
15. J. Yokota, and T. Kohno Molecular footprints of human lung cancer progression Cancer Sc 95 2004 197 204
16. C. Moon, Y. Oh, and J.A. Roth Current status of gene therapy for lung cancer and head and neck cancer Clin Cancer Res 9 2003 5055 5067
17. E.A. Sausville Complexities in the development of cyclin-dependent kinase inhibitor drugs Trend Mol Med 8 Suppl. 2002 S32 S37
18. O. Tetsu, and F. McCormick Proliferation of cancer cells despite CDK2 inhibition Cancer Cell 3 2003 233 245
19. S. Ortega, I. Prieto, and J. Odajima Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice Nat Genet 35 2003 25 31
20. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. In: Proceedings of ASCO, 2004, Available from: http://www.asco.org/ac/1,1003,_12- 002643-00_18-0026-00_19-00678,00.asp
21. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
22. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib New Eng J Med 350 2004 2129 2139
23. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinb and erlotinib PNAS 101 2004 13306 13311
24. A.A. Adjei Blocking oncogenic ras signalling for cancer therapy JNCI 93 2001 1062 1074
25. B.E. Johnson, and J.V. Heymach Farnesyl transferase inhibitors for patients with lung cancer Clin Cancer Res 10 Suppl. 2004 4254s 4257s
26. J.F. Lyons, S. Wilhelm, and B. Hibner Discovery of a novel Raf kinase inhibitor Endocr-Relat Cancer 8 2001 219 225
27. Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). In: Proceedings of ASCO, 2004. Available from: http://www.asco.org/ac/1,1003,_12- 002643-00_18-0026-00_19-003618,00.asp